CERVICAL CANCER VACCINES MARKET ANALYSIS

Cervical Cancer Vaccines Market, By Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2018 - 2026

Published In : Jul 2019
Code : CMI2931
Pages :145
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Cervical Cancer Vaccines Market - Restraints

High cost associated with the treatment of cervical cancer is expected to hamper growth of the global cervical cancer vaccines market during the forecast period. For instance, according to National Center for Biotechnology Information (NCBI) 2017, the cost of cervical cancer treatment ranged from US$ 368 – US$ 11,400 depending on the type of hospital and treatment involved. HPV vaccination is likely to be very cost-effective with an incremental cost per disability-adjusted life year (DALY) averted in the range US$ 780 – US$ 1,120. However, under list prices for Cervarix and Gardasil in Vietnam, the incremental cost per DALY averted for HPV vaccination can exceed US$ 8000.